ArticleScientific reports2025
The effects of the Wnt/β-catenin signaling pathway on the in vitro differentiation of rat BMSCs into leydig cells.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Electrophysiology and Mathematical Modeling for Precision Diagnosis of Infertility.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Late-onset hypogonadism (LOH) refers to sexual and non-sexual symptoms in men caused by age-related decreases in circulating testosterone. Leydig cells (LCs) transplantation is considered to be one of a viable approach for LOH therapy, but the limited source of LCs limits the application of this approach. The aim of this study was to induce the directed differentiation of rat bone marrow mesenchymal stem cells (BMSCs) into LCs in vitro, and explore the potential involvement of Wnt/β-catenin signaling pathway in the differentiation process. BMSCs were extracted from rats and characterized by flow cytometry for positive rates of mesenchymal stem cell markers CD29, CD44, CD90, and the hematopoietic marker CD45. BMSCs were divided into three groups: Control, Wnt agonist (CHIR-99021), and Wnt inhibitor (LGK-974), each incubated for 14 days. ELISA and RT-qPCR were used to verify the protein and mRNA expression of β-catenin, LRP5 and TCF, the key factors in Wnt/β-catenin signaling pathway. The average fluorescence intensity of 3β-hydroxysteroid dehydrogenase (3β-HSD) on the surface of LCs was detected by immunofluorescence (IF) assay. The content of testosterone secreted in cell culture medium was detected by ELISA. The results of flow cytometry indicated that we successfully extracted and cultured BMSCs. Moreover, post 14 days of incubation, the changes of β-catenin, LRP5 and TCF, at the protein and mRNA level demonstrate successful intervention in the activation and inhibition of the intracellular Wnt/β-catenin signaling pathway. Compared with the control group, the LCs surface marker 3β-HSD expression intensity in the CHIR-99,021 group was significantly increased by 69% (p < 0.01), while significantly decreased by 59% in LGK-974 group (p < 0.01). The ELISA results indicated a higher testosterone concentration in the CHIR-99,021 group (359.58 ± 17.46 pg/mL) than in the control (225.31 ± 15.42 pg/mL) and LGK-974 groups (183.67 ± 4.47 pg/mL), and the difference was statistically significant (p < 0.05). This study successfully demonstrates the directed differentiation of BMSCs into LCs under the action of inducers. We verified that the Wnt/β-catenin signaling pathway is involved in this differentiation process. The idea proposed in our study for efficiently inducing differentiation of BMSCs into LC in vitro, may provide a safe and sustainable LC source for developing clinically feasible cell transplantation-based LOH therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.